Imunon Inc Stock Performance
| IMNN Stock | USD 0.88 0.02 2.22% |
Imunon has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.28, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Imunon's returns are expected to increase less than the market. However, during the bear market, the loss of holding Imunon is expected to be smaller as well. Imunon Inc right now retains a risk of 3.99%. Please check out Imunon potential upside, as well as the relationship between the kurtosis and day typical price , to decide if Imunon will be following its current trending patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Imunon Inc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Imunon may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Last Split Factor 1:15 | Last Split Date 2022-03-01 |
1 | Acquisition by Michael Tardugno of 12500 shares of Imunon at 0.8305 subject to Rule 16b-3 | 12/18/2024 |
2 | Acquisition by Fritz Frederick J. of 2000 shares of Imunon at 4.686 subject to Rule 16b-3 | 01/17/2025 |
3 | Imunon director Donald Braun acquires 29,480 worth of shares - MSN | 01/30/2025 |
4 | Acquisition by Braun Donald P of 2000 shares of Imunon at 1.32 subject to Rule 16b-3 | 01/31/2025 |
5 | Insider Trading | 02/18/2025 |
6 | IMUNON Announces Translational Data from Phase 12 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer | 02/19/2025 |
7 | IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 | 02/20/2025 |
8 | IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19 | 02/26/2025 |
9 | Imunon Inc Q4 2024 Earnings Call Highlights Promising Advances Amid Financial Challenges | 02/28/2025 |
10 | Imunon, Inc. Earnings Call Clinical Success Amid Financial Challenges - TipRanks | 03/03/2025 |
| Begin Period Cash Flow | 5.8 M |
Imunon |
Imunon Relative Risk vs. Return Landscape
If you would invest 84.00 in Imunon Inc on December 13, 2024 and sell it today you would earn a total of 4.00 from holding Imunon Inc or generate 4.76% return on investment over 90 days. Imunon Inc is currently generating 0.1534% in daily expected returns and assumes 3.9878% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Imunon, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Imunon Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Imunon's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Imunon Inc, and traders can use it to determine the average amount a Imunon's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0385
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMNN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.99 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Imunon is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Imunon by adding it to a well-diversified portfolio.
Imunon Fundamentals Growth
Imunon Stock prices reflect investors' perceptions of the future prospects and financial health of Imunon, and Imunon fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Imunon Stock performance.
| Return On Equity | -2.11 | ||||
| Return On Asset | -0.76 | ||||
| Current Valuation | 8.18 M | ||||
| Shares Outstanding | 14.62 M | ||||
| Price To Book | 3.04 X | ||||
| Price To Sales | 17.94 X | ||||
| Gross Profit | (1.67 M) | ||||
| EBITDA | (19.13 B) | ||||
| Net Income | (18.62 B) | ||||
| Cash And Equivalents | 42.11 M | ||||
| Cash Per Share | 5.93 X | ||||
| Total Debt | 1.14 B | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 6.52 X | ||||
| Book Value Per Share | 0.29 X | ||||
| Cash Flow From Operations | (18.85 B) | ||||
| Earnings Per Share | (1.62) X | ||||
| Market Capitalization | 12.91 M | ||||
| Total Asset | 9.72 M | ||||
| Retained Earnings | (406.8 B) | ||||
| Working Capital | 3.22 M | ||||
About Imunon Performance
By examining Imunon's fundamental ratios, stakeholders can obtain critical insights into Imunon's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Imunon is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 786.36 | 816.73 | |
| Return On Tangible Assets | -1.9 K | -1.8 K | |
| Return On Capital Employed | 4.01 | 4.21 | |
| Return On Assets | -1.9 K | -1.8 K | |
| Return On Equity | (4.39) | (4.17) |
Things to note about Imunon Inc performance evaluation
Checking the ongoing alerts about Imunon for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Imunon Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Imunon Inc has some characteristics of a very speculative penny stock | |
| Imunon Inc had very high historical volatility over the last 90 days | |
| Imunon Inc has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (18.62 B) with loss before overhead, payroll, taxes, and interest of (1.67 M). | |
| Imunon Inc currently holds about 42.11 M in cash with (18.85 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Imunon Inc has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Bernards Rene of 5527 shares of Lixte Biotechnology at 2.51 subject to Rule 16b-3 |
- Analyzing Imunon's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Imunon's stock is overvalued or undervalued compared to its peers.
- Examining Imunon's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Imunon's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Imunon's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Imunon's stock. These opinions can provide insight into Imunon's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.